17 October 2024

Osteopore partners with NASDAQ-listed CytoMed to advance MSC-powered regeneration

Highlights

- **Osteopore (OSX) signs a collaboration agreement with CytoMed Therapeutics Limited (CytoMed) to combine CytoMed's mesenchymal stem cells (MSCs) with OSX's bioresorbable scaffolds.**
- **NASDAQ-listed CytoMed (NASDAQ: GDTC) is a leading-edge biopharmaceutical company specialising in off-the-shelf allogeneic cancer therapeutics and regenerative medicine.**
- **CytoMed's cGMP lab manufactures clinical-grade allogeneic umbilical cord-derived mesenchymal stem cells (UC-MSCs), amongst others**
- **UC-MSCs are highly effective for targeted tissue regeneration and have demonstrated a strong clinical track record among clinicians and researchers.**
- **The agreement expands Osteopore into the scaffold-based cell therapy market, which is projected to surpass USD 4.39b by 2034.**[1]

Australian-Singaporean regenerative medicine company **Osteopore Limited** (**ASX: OSX**; **Osteopore** or **the Company**) – a global leader in 3D-printed biomimetic and bioresorbable implants – is excited to announce the signing of a collaboration agreement by its subsidiary Osteopore International Pte Ltd and NASDAQ-listed biopharmaceutical company CytoMed Therapeutics Limited (**CytoMed**).

[1] https://www.precedenceresearch.com/scaffold-technology-market

NASDAQ-listed CytoMed (NASDAQ: GDTC) is a Singapore-based biopharmaceutical company, which seeks to leverage its proprietary technology to develop donor-derived cell-based allogeneic therapies for cancer and age-related degenerative diseases. Recently, they secured approval from Singapore's Health Sciences Authority (HSA) for a first-in-human donor allogeneic Phase 1 clinical trial with Singapore's National University Hospital (NUH) as principal investigator.

In September 2024, CytoMed recently gained access to cord blood, a rare and expensive biomaterial with potential for regenerative medicine, through an acquisition of a cord blood banking license and assets.[2]

MSCs have demonstrated a strong clinical track record due to their mature isolation protocols, safety, and immunomodulatory properties. Based on a report published in 2021, more than 1,100 clinical trials had been registered in the areas of traumatology, neurology, cardiology, and neurology tissues and mitigating inflammation – more importantly all of them reported positive results with no serious adverse events.[3]

As research continues to progress, MSCs are emerging as a key element in creating advanced therapies that enhance the body's natural healing power. Their application demonstrates significant potential for transforming healthcare approaches to repairing damaged tissues and improving patient outcomes.[4]

OSX Chairman Mark Leong is an independent non-executive director of CytoMed.

---

[2] NASDAQ Press Release, https://investor.cytomed.sg/news-and-events/news/news-details/2024/CytoMed-Therapeutics-completes-cash-acquisition-of-Cord-Blood-Banking-Licence-and-Assets-expanding-CytoMeds-strategy-to-cord-blood-derived-biologics-through-subsidiary-LongevityBank--2024-eactCiNMkm/default.aspx, 3 October 2024

[3] https://www.sciencedirect.com/science/article/pii/S018844092030638X

[4] https://www.mdpi.com/2073-4409/8/8/886

Under the scope of the 18-month agreement, Osteopore and CytoMed will set up a Technology Advisory Committee (TAC) comprising one nominee from each party to assess co-development and resource utilisation opportunities.

Subsequently, Osteopore and CytoMed may seek third-party funding to support growth and development opportunities in scaffold-based cell therapy.

Key highlights of the collaboration agreement:

- **Capabilities and expertise:** The collaboration will leverage Osteopore's proprietary scaffold-based technology and CytoMed's cell-based therapeutic capabilities.
- **Joint development:** The parties will work together to co-design scaffold-based cellular products.
- **Clinical testing:** The collaboration will pave the way for pre-clinical studies to validate and progress the development of scaffold-based cellular products.
- **Commercialisation strategy:** Leveraging their networks and resources, the parties will collaborate on the commercialisation runway for scaffold-based cellular products.

Commenting on Osteopore's goal to revolutionise tissue regeneration by harnessing MSCs and scaffold-based cell therapy, Chairman Mark Leong stated:

"Together with our innovative scaffolds, MSCs will play a pivotal role in tissue repair, offering exceptional safety, accessibility, and the power to speed up healing and recovery. This is the future of tissue regeneration, where structural innovation meets cellular healing.

"The integration of CytoMed's clinical-grade UC-MSCs with our scaffold technology, combined with our shared commitment to regenerative medicine, creates powerful synergies that can significantly enhance patient outcomes," stated Mr. Leong.

Commenting on the synergies created by CytoMed's revolutionary collaboration with Osteopore, Chairman Peter Choo said:

"This collaboration marks a significant step forward in CytoMed's expanding focus on regenerative medicine and longevity.

"Osteopore's proven scaffold technology aligns perfectly with our goal of leveraging our high-quality UC-MSCs to new and promising applications for an ageing world," said Mr Choo.

In *The Future of Medtech in Australia*, RSM highlighted Osteopore's 'bright future as a regenerative medicine leader'.

Osteopore is committed to broadening its collaboration with leading-edge businesses and expanding its presence in nascent markets to continue pushing the boundaries of regenerative medicine.

The agreement further expands Osteopore's business into the scaffold-based cell therapy market, which is expected to grow at a CAGR of 10% and surpass a projected market size of USD 4.39 billion by 2034[5].

This announcement dated 17 October 2024 has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

Dr Yujing Lim
Chief Executive Officer
Osteopore Limited
E: lim_yujing@osteopore.com

Isaac Stewart
Media & Investor Relations
Purple
E: istewart@purple.au

About Osteopore Limited

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

[5] https://www.precedenceresearch.com/scaffold-technology-market

About CytoMed

Incorporated in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore's leading research and development agency in the public sector. It is a biopharmaceutical company focused on harnessing its licensed proprietary technologies, namely gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell, to create novel cell-based allogeneic immunotherapies for the treatment of various human cancers.

The development of novel technologies has been inspired by the clinical success of existing CAR-T therapies in treating haematological malignancies, as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumours.
https://w2.cytomed.sg/

Forward-Looking Statements

Some of the statements appearing in this announcement may be similar to forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things.

Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by several factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control. The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement. You are cautioned not to place undue reliance on any forward-looking statement.

The forward-looking statements in this announcement reflect views held only as of the date of this announcement. This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their advice before making any investment decision.